Stockreport

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 [Yahoo! Finance]

OnKure Therapeutics, Inc. - Class A  (OKUR) 
PDF -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of P [Read more]